Optimizing drug discovery by Investigative Toxicology : Current and future trends

Lade...
Vorschaubild
Dateien
Beilmann_2-buzlrcalpi8x1.pdf
Beilmann_2-buzlrcalpi8x1.pdfGröße: 2.94 MBDownloads: 635
Datum
2019
Autor:innen
Beilmann, Mario
Boonen, Harrie
Czich, Andreas
Dear, Gordon
Hewitt, Philip
Steger-Hartmann, Thomas
et al.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
ArXiv-ID
Internationale Patentnummer
Link zur Lizenz
Angaben zur Forschungsförderung
European Union (EU): 681002
Projekt
EUToxRisk21
Open Access-Veröffentlichung
Open Access Gold
Sammlungen
Core Facility der Universität Konstanz
Gesperrt bis
Titel in einer weiteren Sprache
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Alternatives to Animal Experimentation : ALTEX. 2019, 36(2), pp. 289-313. ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.1808181
Zusammenfassung

Investigative Toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, Investigative Toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adhering to the 3R (Replacement, Reduction and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, Investigative Toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use of inappropriate animal models. Progress in Investigative Toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an "Investigative Toxicology Think-Tank", which aimed to enhance the interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights Investigative Toxicology's position by identifying key challenges and perspectives.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Konferenz
Rezension
undefined / . - undefined, undefined
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Datensätze
Zitieren
ISO 690BEILMANN, Mario, Harrie BOONEN, Andreas CZICH, Gordon DEAR, Philip HEWITT, Mardas DANESHIAN, Thomas HARTUNG, Marcel LEIST, Costanza ROVIDA, Thomas STEGER-HARTMANN, 2019. Optimizing drug discovery by Investigative Toxicology : Current and future trends. In: Alternatives to Animal Experimentation : ALTEX. 2019, 36(2), pp. 289-313. ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.1808181
BibTex
@article{Beilmann2019Optim-44428,
  year={2019},
  doi={10.14573/altex.1808181},
  title={Optimizing drug discovery by Investigative Toxicology : Current and future trends},
  number={2},
  volume={36},
  issn={1868-596X},
  journal={Alternatives to Animal Experimentation : ALTEX},
  pages={289--313},
  author={Beilmann, Mario and Boonen, Harrie and Czich, Andreas and Dear, Gordon and Hewitt, Philip and Daneshian, Mardas and Hartung, Thomas and Leist, Marcel and Rovida, Costanza and Steger-Hartmann, Thomas}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/44428">
    <dc:language>eng</dc:language>
    <dc:creator>Boonen, Harrie</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-01-07T14:42:10Z</dc:date>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/44428/1/Beilmann_2-buzlrcalpi8x1.pdf"/>
    <dc:contributor>Czich, Andreas</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/44428/1/Beilmann_2-buzlrcalpi8x1.pdf"/>
    <dc:creator>Dear, Gordon</dc:creator>
    <dcterms:abstract xml:lang="eng">Investigative Toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, Investigative Toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adhering to the 3R (Replacement, Reduction and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, Investigative Toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use of inappropriate animal models. Progress in Investigative Toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an "Investigative Toxicology Think-Tank", which aimed to enhance the interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights Investigative Toxicology's position by identifying key challenges and perspectives.</dcterms:abstract>
    <dc:contributor>Boonen, Harrie</dc:contributor>
    <dc:creator>Beilmann, Mario</dc:creator>
    <dc:contributor>Beilmann, Mario</dc:contributor>
    <dc:contributor>Steger-Hartmann, Thomas</dc:contributor>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:contributor>Rovida, Costanza</dc:contributor>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-01-07T14:42:10Z</dcterms:available>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Daneshian, Mardas</dc:creator>
    <dc:creator>Hewitt, Philip</dc:creator>
    <dc:contributor>Dear, Gordon</dc:contributor>
    <dcterms:issued>2019</dcterms:issued>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:title>Optimizing drug discovery by Investigative Toxicology : Current and future trends</dcterms:title>
    <dc:creator>Czich, Andreas</dc:creator>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/44428"/>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <dc:contributor>Hewitt, Philip</dc:contributor>
    <dc:creator>Steger-Hartmann, Thomas</dc:creator>
    <dc:creator>Rovida, Costanza</dc:creator>
    <dc:contributor>Daneshian, Mardas</dc:contributor>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen